TRX103
BiologicalTRX103 infusion via central line.
NCT Number: NCT06462365
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 1
City of Hope, Duarte, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
TRX103 infusion via central line.
Time frame: Up to a year
Time frame: Up to day 42
Time frame: At 3-month, 6-month, and 1-year.
Time frame: Day 0 to Day +100 day
Time frame: Day 0 to Day +100 day
Time frame: Day +100 through Day +365
Time frame: Up to a year
Contact information is provided by the study sponsor or research team.
Tr1X, Inc.
Industry
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06206174
Acute Lymphoblastic Leukemia, Adult, Acute Myeloid Leukemia
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT03555955
Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06960993
Blood Protein Disorders, Bone Marrow Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07044544
Acute Myeloid Leukemia, Bone Marrow Diseases
Birmingham, Alabama, United States
View Trial Details